8-K: Cocrystal Pharma Extends Phase 2a Influenza Study Enrollment Due to Low Infection Rates

Cocrystal Pharma is extending enrollment in its Phase 2a human challenge study for its influenza drug candidate, CDI-42344, due to unexpectedly low infection rates among participants.

Summary

• Cocrystal Pharma is extending enrollment in its Phase 2a human challenge study of CDI-42344, an oral influenza PB2 inhibitor.
• The extension is due to a low rate of influenza infection among participants challenged with the H3N2 viral strain.
• The study is evaluating the safety, tolerability, pharmacokinetics, antiviral activity, and clinical measurements of CC-42344.
• The company had previously announced full enrollment of 78 subjects in May 2024.
• While the drug showed a favorable safety and tolerability profile, the low infectivity rate hindered antiviral data analysis.
• The company is working on a protocol amendment to ensure necessary infection rates among enrolled subjects.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the study delay and low infection rates, but the company remains optimistic about the drug's potential and safety profile.

Positives

• CC-42344 has demonstrated a favorable safety and tolerability profile in the Phase 2a study.
• There have been no serious adverse events or drug-related discontinuations reported in the study.
• CC-42344 has shown excellent in vitro antiviral activity against various influenza strains, including those resistant to Tamiflu and Xofluza.
• The drug has a unique mechanism of action with a high barrier to developing resistance.
• The company is actively working to address the low infection rate issue by extending enrollment and amending the study protocol.

Negatives

• The low infectivity rate of the challenge influenza strain has hindered antiviral data analysis.
• The study needs to be extended to achieve the necessary infection rates among enrolled subjects.
• The low infection rate has delayed the ability to determine clinical endpoints for evaluating antiviral molecules.

Risks

• The company faces the risk of not achieving the necessary infection rates even with extended enrollment.
• There is a risk that the protocol amendment may not be approved by the MHRA.
• The development of effective treatments and/or vaccines by competitors could impact the success of CC-42344.
• Potential mutations in the virus could result in variants that are resistant to CC-42344.

Future Outlook

The company plans to extend enrollment in the Phase 2a study and work with the clinical research organization to prepare a protocol amendment for approval by the MHRA to ensure necessary infection rates among enrolled study subjects.

Management Comments

• Sam Lee, Ph.D., Cocrystals President and co-CEO, stated that the low infectivity obtained in this study hindered antiviral data analysis.
• Sam Lee also mentioned that they remain optimistic about CC-42344 due to its unique mechanism of action and high barrier to developing resistance.
• Management is encouraged by CC-42344's favorable safety and tolerability profile.

Industry Context

The announcement highlights the challenges in developing effective antiviral treatments for influenza, especially with the emergence of new strains and resistance to existing drugs. The company's focus on a novel mechanism of action is relevant given the need for new treatment options.

Comparison to Industry Standards

• The Phase 2a study is a standard approach for evaluating the safety and efficacy of new drug candidates.
• The use of a human challenge model is a common method for assessing antiviral activity, but the low infection rate highlights the variability in these studies.
• The company's focus on a novel PB2 inhibitor is in line with the industry's efforts to develop new antiviral treatments with different mechanisms of action to combat resistance.
• Other companies such as Roche (Tamiflu) and Shionogi (Xofluza) have developed influenza antivirals, but resistance is a growing concern, making Cocrystal's approach potentially valuable.

Stakeholder Impact

• Shareholders may be concerned about the delay in the study and the potential impact on the drug's development timeline.
• Employees may be impacted by the need to extend the study and adjust timelines.
• Patients may be impacted by the delay in the development of a new influenza treatment.

Next Steps

• The company will prepare a protocol amendment for approval by the MHRA.
• The company will extend enrollment in the Phase 2a study.
• The company will continue to monitor the safety and tolerability of CC-42344.

Key Dates

Keywords

Influenza, Antiviral, Phase 2a Study, CDI-42344, Clinical Trial, PB2 Inhibitor, Infection Rate, Drug Development, Cocrystal Pharma